Skip to main content
OpenTrials
Completed

NCT Number: NCT01534520

Self-administered Intravaginal 2% Lidocaine Gel Prior to Intrauterine Device Insertion in Nulliparous Women

This study is designed to evaluate if self-inserted intravaginal 2% lidocaine gel is effective at decreasing pain during intrauterine device insertion in nulliparous women.

Completed

Looking for future studies?

Notify Me

Key information

Age range

14 year–55 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Magee-Womens Hospital

Pittsburgh, Pennsylvania, 15213, United States

About this study

Intrauterine devices (IUDs) are among the most effective forms of reversible contraception. Numerous studies demonstrate their safety and efficacy in nulliparous women, however, uptake of IUDs in this group is low. One of the major barriers to women obtaining IUDs is fear of pain during insertion, as studies do demonstrate that nulliparous women experience more pain than parous women during IUD insertion. Studies evaluating various methods for pain control during IUD insertion have shown conflicting results, leaving the question unanswered as to what is the best method to decrease pain during IUD insertion.

This study aims to evaluate a novel approach to pain control by having women self-insert lidocaine gel into the vagina at least 5 minutes prior to IUD insertion. This will overcome some of the barriers from other studies where there may not have been ample time for the lidocaine to take effect, while at the same time eliminating the need for women to have multiple speculum exams. Although this is a novel approach to administering an anesthetic, we believe women will be interested in any intervention that may potentially alleviate pain during IUD insertion.

If this study does demonstrate that pain is decreased with self-inserted lidocaine compared to placebo gel, this will potentially eliminate one large barrier to nulliparous women receiving IUDs. Increased uptake of highly effective contraception in nulliparous women is just one of the many steps necessary towards decreasing unintended pregnancy.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Nulliparous, as defined in this study as no history of pregnancy ≥ 24 weeks gestational age
  • Desires insertion of either levonorgestrel-releasing IUD (LNG-IUD) or copper T380A IUD (Cu-IUD)
  • No history of pregnancy in the last 6 weeks
  • Able to provide written informed consent in English and comply with all study procedures

Exclusion criteria

  • Known allergy or hypersensitivity to lidocaine or other amino amide local anesthetics
  • Prior failed IUD insertion
  • Prior IUD use
  • Use of narcotic or benzodiazepine medication within the last 24 hours
  • U.S. Centers for Disease Control Medical Eligibility Criteria (MEC) category 3 or 4 classification for use of an IUD
  • Positive pregnancy test or reasonable risk of pregnancy due to unprotected heterosexual intercourse since the last menstrual period

Treatment and study plan

Lidocaine

Drug

Intravaginal insertion of 4mL 2% lidocaine gel

Other names: Lidocaine Jelly, Lidocaine Hydrochloride

Placebo

Drug

KY Jelly

Other names: K-Y Jelly, water based lubricant

Primary outcomes

  1. Change in Pain From Baseline to IUD Insertion

    Time frame: change in pain score from baseline (before IUD insertion) to time of IUD insertion

    To assess change in pain from baseline to IUD insertion measured on a visual analog scale (VAS) from 0 mm (no pain) to 100 mm (worst pain in patient's life). This pain assessment was prior to (baseline) and at the time of IUD insertion following vaginal self-administration of study gel (either 2% lidocaine gel or placebo gel).

Secondary outcomes

  1. To Evaluate Patient Experience of Self-inserting the Intravaginal Study Gel Prior to IUD

    Time frame: After inserting the gel but prior to IUD insertion

    Number of participants who rated self-application of study gel as "some what easy" or "very easy" on Likert scale

  2. Percentage of IUDs Considered by Physicians Easy to Insert

    Time frame: Directly after IUD insertion

    The physician who conducted the study visit and IUD insertion was asked about the difficulty/ease in placing the IUD immediately following the procedure and the percentage of IUD insertions considered to be "easy" was calculated for each study group.

  3. Need for Pain Medication up to 7 Days

    Time frame: 7 days post-insertion

    Number of women taking pain medication for at least one day following IUD insertion

Sponsors and collaborators

Lead sponsor

University of Pittsburgh

Other

Collaborators

  • Society of Family Planning

Registry information

Official study title

Self-administered Intravaginal 2% Lidocaine Gel Prior to Intrauterine Device Insertion in Nulliparous Women: a Randomized Controlled Trial

Acronym: LIVIIN

Important dates

Study start
2012
Primary completion
2013
Study completion
2013
First posted
Feb 16, 2012
Registry last updated
Dec 22, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.